following.10A combination of a CDK4/6 inhibitor and endocrine therapy is currently the first choice because the addition of CDK 4/6 inhibitors to endocrine therapy is associated with improved survival and maintained or improved quality of life compared to other endocrine therapies.3,4,5,6,7,8,...
There was also a moderate improvement in overall response rate (ORR) with relatlimab plus nivolumab and chemotherapy compared with nivolumab plus chemotherapy (51.3% vs 43.7%, respectively; difference = 7.6%). The median duration of response was 10.1 months in the relatlimab plus nivolumab...
To our knowledge, this is the first RWS in China to systematically analyse the treatment of patients with de novo stage IV breast cancer. Patients who were enrolled in the CSCO BC database and Hebei Breast Center Database between 2004 and 2018 had a better survival advantage after surgical re...
236MO Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based studydoi:10.1016/j.annonc.2024.08.179M. de GraafR. GielenS. BalduzziS. SieslingS. LinnM. KokAnnals of Oncology
’s anti-PD-1 therapy, met its overall survival (OS) endpoint, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant) for the treatment of patients with...
complete response with incomplete bone marrow recovery, 87.2% a partial response (PR), 3.7% a PR with lymphocytosis, 4.6% stable disease, and 0.9% progressive disease.2 The estimated 18-month progression-free survival (PFS) rate was 88.6%, and the estimated overall survival rate was 95.1%. ...
The median OS was 27.8 months (95% CI: 9.9–not estimable), and the 12-month survival rate was 69.6% (95% CI: 46.6–84.2). Table 4. Summary of Anticancer Activity (Safety Population) ResponseCohort A KRAS-mtNSCLC (N = 25)n (%)Cohort B Squamous NSCLC(N = 25)n (%) n (%)95...
Based on the evidence, using taxanes in early-stage BC improves the survival rate and reduces the likelihood of cancer recurrence. However, using taxanes is also associated with side effects such as febrile neutropenia and neuropathy. Therefore, the decision to include taxanes in the treatment ...
targets MDM2 within p53-mutated/deficient TNBC cells, inducing proteasome-mediated degradation through high-affinity binding and VHL recruitment, thereby promoting TC apoptosis without toxicity to normal cells and significantly extending survival, offering an innovative potential therapeutic strategy for TNBC....
Ricardo Costa, MD, MSC, discusses the use of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab monotherapy, in patients with high-risk, early-stage triple-negative breast cancer.